Blood Transfusion and Survival for Resected Adrenocortical Carcinoma: A Study from the United States Adrenocortical Carcinoma Group

Abstract

Perioperative blood transfusion is associated with decreased survival in pancreatic, gastric, and liver cancer. The effect of transfusion in adrenocortical carcinoma (ACC) has not been studied. Patients with available transfusion data undergoing curative-intent resection of ACC from 1993 to 2014 at 13 institutions comprising the United States Adrenocortical Carcinoma Group were included. Factors associated with blood transfusion were determined. Primary and secondary end points were recurrence-free survival (RFS) and overall survival (OS), respectively. Out of 265 patients, 149 were included for analysis. Out of these, 57 patients (38.3%) received perioperative transfusions. Compared to nontransfused patients, transfused patients more commonly had stage 4 disease (46% vs 24%, P = 0.01), larger tumors (15.8 vs 10.2 cm, P < 0.001), inferior vena cava involvement (24.6% vs 5.4%, P = 0.002), additional organ resection (78.9% vs 36.3%, P < 0.001), and major complications (29% vs 2%, P < 0.001). Transfusion was associated with decreased RFS (8.9 vs 24.7 months, P = 0.006) and OS (22.8 vs 91.0 months, P < 0.001). On univariate Cox regression, transfusion, stage IV, hormonal hypersecretion, and adjuvant therapy were associated with decreased RFS. On multivariable analysis, only transfusion [hazard ratio (HR) = 1.7, 95% confidence interval (CI) 51.0–2.9, P = 0.04], stage IV (HR = 3.2, 95% CI = 1.7–5.9, P < 0.001), and hormonal hypersecretion (HR = 2.6, 95% CI = 1.5–4.2, P < 0.001) were associated with worse RFS. When applying this model to OS, similar associations were seen (transfusion HR = 2.0, 95% CI = 1.1–3.8, P = 0.02; stage 4 HR = 6.2, 95% CI = 3.1–12.4, P < 0.001; hormonal hypersecretion HR = 3.5, 95% CI = 1.9–6.4, P < 0.001). There was no difference in outcomes between patients who received 1 to 2 units versus >2 units of packed red blood cells in median RFS (8.9 vs 8.4 months, P = 0.95) or OS (26.5 vs 18.6 months, P = 0.63). Peri-operative transfusion is associated with earlier recurrence and decreased survival after curative-intent resection of ACC. Strategies and protocols to minimize blood transfusion should be developed and followed.

Get full access to this article

View all access options for this article.

References

Ayala-Ramirez

, Jasim

, Feng

Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center.

Eur J Endocrinol 2013; 169: 891–9.

Margonis

G.A.

, Kim

, Prescott

J.D.

Adrenocortical carcinoma: impact of surgical margin status on long-term outcomes.

Ann Surg Oncol 2016; 23: 134–41.

Schulick

R.D.

, Brennan

M.F.

Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma.

Ann Surg Oncol 1999; 6: 719–26.

Livhits

, Li

, Yeh

M.W.

Surgery is associated with improved survival for adrenocortical cancer, even in metastatic disease.

Surgery 2014; 156: 1531–40; discussion 1540–1.

Margonis

G.A.

, Kim

, Tran

T.B.

Outcomes after resection of cortisol-secreting adrenocortical carcinoma.

Am J Surg 2016; 211: 1106–13.

Kim

, Margonis

G.A.

, Prescott

J.D.

Curative surgical resection of adrenocortical carcinoma: determining long-term outcome based on conditional disease-free probability.

Ann Surg 2017; 265: 197–204.

Postlewait

L.M.

, Ethun

C.G.

, Tran

T.B.

Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US adrenocortical carcinoma group.

J Am Coll Surg 2016; 222: 480–90.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology neuroendocrine tumors, 2014. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed February 3, 2016.

Fassnacht

, Johanssen

, Quinkler

Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification.

Cancer 2009; 115: 243–50.

10.

Lughezzani

, Sun

, Perrotte

The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation.

Eur J Cancer 2010; 46: 713–9.

11.

Bilimoria

K.Y.

, Shen

W.T.

, Elaraj

Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors.

Cancer 2008; 113: 3130–6.

12.

Bagante

, Tran

T.B.

, Postlewait

L.M.

Neutrophillymphocyte and platelet-lymphocyte ratio as predictors of disease specific survival after resection of adrenocortical carcinoma.

J Surg Oncol 2015; 112: 164–72.

13.

Sutton

J.M.

, Kooby

D.A.

, Wilson

G.C.

Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-institutional study.

J Gastrointest Surg 2014; 18: 1575–87.

14.

Kneuertz

P.J.

, Patel

S.H.

, Chu

C.K.

Effects of peri-operative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma.

Ann Surg Oncol 2011; 18: 1327–34.

15.

Squires

M.H.

III , Kooby

D.A.

, Poultsides

G.A.

Effect of perioperative transfusion on recurrence and survival after gastric cancer resection: a 7-institution analysis of 765 patients from the US Gastric Cancer Collaborative.

J Am Coll Surg 2015; 221: 767–77.

16.

Asahara

, Katayama

, Itamoto

Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma.

World J Surg 1999; 23: 676–80.

17.

Sun

, Wang

, Yao

H.S.

Allogeneic blood transfusion and the prognosis of gastric cancer patients: systematic review and meta-analysis.

Int J Surg 2015; 13: 102–10.

18.

Amato

, Pescatori

Perioperative blood transfusions for the recurrence of colorectal cancer.

Cochrane Database Syst Rev 2006; CD005033.

19.

Perisanidis

, Dettke

, Papadogeorgakis

Transfusion of allogenic leukocyte-depleted packed red blood cells is associated with postoperative morbidity in patients undergoing oral and oropharyngeal cancer surgery.

Oral Oncol 2012; 48: 372–8.

20.

Miki

, Hiro

, Ojima

Perioperative allogeneic blood transfusion, the related cytokine response and long-term survival after potentially curative resection of colorectal cancer.

Clin Oncol (R Coll Radiol) 2006; 18: 60–6.

21.

Postlewait

L.M.

, Squires

M.H.

3rd , Kooby

D.A.

The relationship of blood transfusion with peri-operative and long-term outcomes after major hepatectomy for metastatic colorectal cancer: a multi-institutional study of 456 patients.

HPB 2015; 18: 192–9.

22.

Yeh

J.J.

, Gonen

, Tomlinson

J.S.

Effect of blood transfusion on outcome after pancreaticoduodenectomy for exocrine tumour of the pancreas.

Br J Surg 2007; 94: 466–72.

23.

Edge

S.B.

, Compton

C.C.

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

Ann Surg Oncol 2010; 17: 1471–4.

24.

Dindo

, Demartines

, Clavien

P.A.

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.

Ann Surg 2004; 240: 205–13.

25.

Wang

, Luo

, Huang

Perioperative blood transfusion is associated with worse clinical outcomes in resected lung cancer.

Ann Thorac Surg 2014; 97: 1827–37.

26.

Linder

B.J.

, Thompson

R.H.

, Leibovich

B.C.

The impact of perioperative blood transfusion on survival after nephrectomy for non-metastatic renal cell carcinoma (RCC).

BJU Int 2014; 114: 368–74.

27.

Moriguchi

, Maehara

, Akazawa

Lack of relationship between perioperative blood transfusion and survival time after curative resection for gastric cancer.

Cancer 1990; 66: 2331–5.

28.

Kooby

D.A.

, Stockman

, Ben-Porat

Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases.

Ann Surg 2003; 237: 860–9, discussion 869–70.

29.

Foster

R.S.

Jr. , Foster

J.C.

, Costanza

M.C.

Blood transfusions and survival after surgery for breast cancer.

Arch Surg 1984; 119: 1138–40.

30.

Keller

S.M.

, Groshen

, Martini

Blood transfusion and lung cancer recurrence.

Cancer 1988; 62: 606–10.

31.

Weiden

P.L.

, Bean

M.A.

, Schultz

Perioperative blood transfusion does not increase the risk of colorectal cancer recurrence.

Cancer 1987; 60: 870–4.

32.

Chen

, Zhang

F.J.

, Gong

Effect of perioperative autologous versus allogeneic blood transfusion on the immune system in gastric cancer patients.

J Zhejiang Univ Sci B 2007; 8: 560–5.

33.

Ghio

, Contini

, Mazzei

Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions.

Blood 1999; 93: 1770–7.

34.

Innerhofer

, Tilz

, Fuchs

Immunologic changes after transfusion of autologous or allogeneic buffy coat-poor versus WBC-reduced blood transfusions in patients undergoing arthroplasty. II. Activation of T cells, macrophages, and cell-mediated lympholysis.

Transfusion 2000; 40: 821–7.

35.

Opelz

, Sengar

D.P.

, Mickey

M.R.

Effect of blood transfusions on subsequent kidney transplants.

Transplant Proc 1973; 5: 253–9.